AnaptysBio
ANAB
129 hedge funds and large institutions have $2.85B invested in AnaptysBio in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 18 closing their positions.
136% more call options, than puts
Call options by funds: $88.8M | Put options by funds: $37.7M
61% more capital invested
Capital invested by funds: $1.77B → $2.85B (+$1.08B)
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
26% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 38
4% more funds holding
Funds holding: 124 → 129 (+5)
2.71% more ownership
Funds ownership: 105.96% → 108.67% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$76M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.1M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$33M |
| 4 |
Janus Henderson Group
London,
|
+$26M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$16.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15.1M |
| 4 |
Millennium Management
New York
|
-$11.9M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.17M |
ANAB Hedge Fund Activity: Q3 2018 in Review
129 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2018, worth a combined $2.85B — up 61% from $1.77B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ANAB positions and 18 closed out — a net gain of 6 holders — while 48 added to existing stakes and 38 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $76M. The largest seller was Adage Capital Partners, cutting an estimated $20.7M.
- 129 institutional investors held AnaptysBio (ANAB) as of Q3 2018, up from 124 in Q2 2018.
- Funds reported $2.85B of AnaptysBio stock for Q3 2018, up 61% quarter-over-quarter.
- 24 funds opened new AnaptysBio positions in Q3 2018 and 18 closed out, a net change of +6 holders.
- The largest AnaptysBio buyer in Q3 2018 was PFM Health Sciences, an estimated $76M added.
- The largest AnaptysBio seller in Q3 2018 was Adage Capital Partners, an estimated $20.7M sold.
Based on aggregated 13F filings for Q3 2018.